Cost-variation analysis between different brands of cardiovascular drugs available in the Indian market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20254152Keywords:
Analytical study, Affordability, Cardiovascular diseases, Cost variation, Financial burden, Medication adherenceAbstract
Background: Cardiovascular diseases (CVDs) emerging as a leading cause of mortality in India, access to affordable medications is crucial for managing these conditions. Our study examined the significant cost variations among different brands of cardiovascular drugs available in the Indian market. The study was conducted to find out the cost variation in the cardiovascular drugs available in India and to evaluate the difference in cost of various brands of the same by calculating percentage of variation in cost.
Methods: The analytical study was carried out by taking the cost of a particular drug in the same dosage forms and strength being manufactured by different companies was obtained from July-October 2024 edition of the current index of medical specialities (CIMS) and July-October 2024 edition of monthly index of medical specialties (MIMS) and percentage cost variation was calculated.
Results: Our analysis revealed a wide price variation among various drug brands of cardiovascular drugs. Furosemide 40 mg tablet has shown the highest price variation (1572.86%), while least price variation is seen in hydrochlorothiazide 25 mg tablet (3.98%).
Conclusions: Prices of various drugs used in the treatment of cardiovascular drugs show a wide variation in the Indian market. Medication adherence, community health, and the financial burden of healthcare costs on the country would all be improved by lowering price variation and making drugs more affordable. The findings highlight the urgency of implementing measures to reduce price variations and improve affordability, thereby enhancing healthcare access and mitigating the financial burden on individuals and society. However, it’s important to note the study’s limitations, including the selection of only a subset of drug brands available in CIMS and MIMS for analysis.
Metrics
References
Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: Current epidemiology and future directions. Circulation. 2016;133(16):1605-20. DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.008729
Sreeniwas Kumar A, Sinha N. Cardiovascular disease in India: A 360 degree overview. Med J Armed Forces India. 2020;76(1):1-3. DOI: https://doi.org/10.1016/j.mjafi.2019.12.005
Kundu J, Kundu S. Cardiovascular disease (CVD) and its associated risk factors among older adults in India: Evidence from LASI Wave 1. Clin Epidemiol Glob Health. 2022;13(100937):100937. DOI: https://doi.org/10.1016/j.cegh.2021.100937
Abdul-Aziz AA, Desikan P, Prabhakaran D, Schroeder LF. Tackling the burden of cardiovascular diseases in India: The essential diagnostics list. Circ Cardiovasc Qual Outcomes. 2019;12(4). DOI: https://doi.org/10.1161/CIRCOUTCOMES.118.005195
Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart. 2008;94(1):16-26. DOI: https://doi.org/10.1136/hrt.2007.132951
Ahmad A, Chang J, Chung H, Mohanta G, Parimilakrishnan S, Patel I. The role of pharmacoeconomics in current Indian healthcare system. J Res Pharm Pract. 2013;2(1):3. DOI: https://doi.org/10.4103/2279-042X.114081
Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus. 2020;12(5). DOI: https://doi.org/10.7759/cureus.7964
National Health Accounts 2004-05. People’s Archive of Rural India. 2018. Available from: https://ruralindiaonline.org/en/library/resource/national-health-accounts-2004-05/. Accessed on 13 June 2025.
Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020;5(11):e002640. DOI: https://doi.org/10.1136/bmjgh-2020-002640
van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10(1). DOI: https://doi.org/10.1186/1471-2261-10-25
Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int j Med Res Health Sci. 2013;2(1):63-9.
Chawan V, Badwane S, Gawand K, Chhaya M. Analysis of price variation amongst different formulations of anxiolytic drugs available in Indian market. Int J Res Med Sci. 2016;4(6):2398-401. DOI: https://doi.org/10.18203/2320-6012.ijrms20161821
Kumar R, Manu C, Singh D, Lakhani P, Tutu S, Dixit R. The extent of price variation amongst branded antihypertensive drugs and its association with number of pharmaceutical companies. Int J Res Med Sci. 2015;3(10):2800-6. DOI: https://doi.org/10.18203/2320-6012.ijrms20150689
Ashiwaju BI, Orikpete OF, Alade EY, Raji A, Adesanya AO, Nwankwo TC. Impact of drug price regulation on patient access to medicines: a systematic review. Matrix Sci Pharma. 2023;7(4):112-8. DOI: https://doi.org/10.4103/mtsp.mtsp_23_23
Pandey KR, Meltzer DO. Financial burden and impoverishment due to cardiovascular medications in low and middle income countries: an illustration from India. PLoS One. 2016;11(5):e0155293. DOI: https://doi.org/10.1371/journal.pone.0155293
Downloads
Published
How to Cite
Issue
Section
